Fulcrum Therapeutics (FULC) Return on Sales (2020 - 2025)

Fulcrum Therapeutics (FULC) has 6 years of Return on Sales data on file, last reported at 0.01% in Q2 2025.

• Return on Sales for Q2 2025 came in at 0.01%, down 2.0% year-over-year; the trailing twelve-month figure through Jun 2025 was 0.01% (down 1.0% YoY), and the FY2024 annual result was 0.0%, up 35.0% from the prior year.
• Return on Sales slipped to 0.01% in Q2 2025 per FULC's latest filing, from 0.0% in the prior quarter.
• Over five years, Return on Sales peaked at 0.01% in Q2 2024 and troughed at 0.84% in Q1 2023.
• A 5-year average of 0.18% and a median of 0.1% in 2022 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2023 and 2024: Return on Sales tumbled 74 bps in 2023, then soared 44 bps in 2024.
• A 5-year view of Return on Sales shows it stood at 0.05% in 2021, then slumped by 722 bps to 0.38% in 2022, then advanced by 26 bps to 0.28% in 2023, then soared by 100 bps to 0.0% in 2024, then tumbled by 653 bps to 0.01% in 2025.
• Business Quant data shows FULC's Return on Sales at 0.01% in Q2 2025, 0.0% in Q4 2024, and 0.0% in Q3 2024.